For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
4
views
66
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      179
      similar
       All similar

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hormone replacement in survivors of childhood cancer and brain tumors: safety and controversies

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Childhood cancer survivors are at risk for developing endocrine disorders, including deficits in growth hormone, thyroid hormone and sex hormones. The influence these hormones have on cell growth and metabolism has raised concerns regarding the safety of their use as treatments in survivors of childhood cancer and brain tumors. This article offers a summary of current knowledge, controversies and areas for future research pertaining to this area.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

          Gary Francis, Steven G Waguespack, Andrew Bauer … (2015)
          Previous guidelines for the management of thyroid nodules and cancers were geared toward adults. Compared with thyroid neoplasms in adults, however, those in the pediatric population exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. Furthermore, therapy that may be recommended for an adult may not be appropriate for a child who is at low risk for death but at higher risk for long-term harm from overly aggressive treatment. For these reasons, unique guidelines for children and adolescents with thyroid tumors are needed.
          Article 0 comments Cited 266 times – based on 0 reviews     Review now
            • Record: found
            • Abstract: found
            • Article: found

            Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

            Adda Grimberg, Sara A. DiVall, Constantin Polychronakos … (2017)
            Background/Aims: On behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, we sought to update the guidelines published in 2003 on the use of growth hormone (GH). Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), we focused on these three diagnoses, thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. Methods: This guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). Results: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. Conclusion: The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.
            Article 0 comments Cited 243 times – based on 0 reviews     Review now
              • Record: found
              • Abstract: found
              • Article: not found

              Hormonal Therapy for Prostate Cancer

              Kunal Desai, Jeffrey McManus, Nima Sharifi (2021)
              Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone deprivation in the 1940s and therefore firmly established the concept that prostate cancer is a highly androgen-dependent disease. Since that time, hormonal therapy has undergone iterative advancement, from the types of gonadal testosterone deprivation to modalities that block the generation of adrenal and other extragonadal androgens, to those that directly bind and inhibit the androgen receptor (AR). The clinical states of prostate cancer are the product of a superimposition of these therapies with nonmetastatic advanced prostate cancer, as well as frankly metastatic disease. Today’s standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists (e.g., leuprolide), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone. The purpose of this review is to provide an assessment of hormonal therapies for the various clinical states of prostate cancer. The advancement of today’s standard of care will require an accounting of an individual’s androgen physiology that also has recently recognized germline determinants of peripheral androgen metabolism, which include HSD3B1 inheritance.
              Article 0 comments Cited 144 times – based on 0 reviews     Review now
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Endocr Connect
                Journal ID (iso-abbrev): Endocr Connect
                Journal ID (hwp): EC
                Title: Endocrine Connections
                Publisher: Bioscientifica Ltd (Bristol )
                ISSN (Electronic): 2049-3614
                Publication date (Electronic): 08 November 2022
                Publication date Collection: 01 January 2023
                Volume: 12
                Issue: 1
                Electronic Location Identifier: e220382
                Affiliations
                [1 ]Department of Pediatric Endocrinology , Wilhelmina Children's Hospital, University Medical Center Utrecht, AB Utrecht, The Netherlands
                [2 ]Princess Máxima Center for Pediatric Oncology , AB Utrecht, The Netherlands
                [3 ]Division of Pediatric Endocrinology , UPMC Children’s Hospitalof Pittsburgh, Pittsburgh, Pennsylvania, USA
                Author notes
                Correspondence should be addressed to W Chemaitilly: chemaitillyw2@ 123456upmc.edu
                Author information
                http://orcid.org/0000-0003-0229-1123
                http://orcid.org/0000-0002-6773-6931
                http://orcid.org/0000-0003-0717-5076
                Article
                Publisher ID: EC-22-0382
                DOI: 10.1530/EC-22-0382
                PMC ID: 9782441
                PubMed ID: 36347051
                SO-VID: 7863b910-e2b1-4142-8b39-6746a9b1a687
                Copyright © © The authors
                License:

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                Date received : 31 October 2022
                Date accepted : 08 November 2022
                Categories
                Subject: Review

                Keywords: childhood cancer,childhood brain tumors,growth hormone,hypothyroidism,hypogonadism
                Data availability:
                Keywords: childhood cancer, childhood brain tumors, growth hormone, hypothyroidism, hypogonadism

                Comments

                Comment on this article

                Related Documents Log